iNKT cells have some unique beneficial biological properties which make them the ideal candidate for adoptive cell transfer approach to treat cancer: (1) they inhibit immunosuppressive myelomonocytic cells in TME via CD1d- cognate recognition (2), (2) the suppression of inhibitory signals from TME, and elimination of CD1d harboring cancer cells along with specific antitumor activity through CAR signaling likely to enhance therapeutic efficacy of CAR-iNKT cells through these synergistic mechanisms (2, 140). Here, CD1D is linked to cancer.